Tillkännagivande • Nov 30
Allied Corp. announced delayed annual 10-K filing On 11/29/2024, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Jul 17
Allied Corp. announced delayed 10-Q filing On 07/16/2024, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Apr 16
Allied Corp. announced delayed 10-Q filing On 04/15/2024, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Mar 30
Allied Corp. Announces Resignation of Santiago Ribero as Director Allied Corp. announced that effective March 20, 2024 Santiago Ribero resigned as a Director of the company Mr. Ribero has moved to the United States and has taken a position in the banking industry, but will continue to have an active role with the Company. Tillkännagivande • Dec 01
Allied Corp. announced delayed annual 10-K filing On 11/30/2023, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Jul 16
Allied Corp. announced delayed 10-Q filing On 07/14/2023, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Jan 19
Allied Corp. announced delayed 10-Q filing On 01/18/2023, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Nov 29
Allied Corp. announced delayed annual 10-K filing On 11/28/2022, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Aug 24
Allied Corp Receives The Brazilian Health Regulatory Agency Approval for Brazilian Import Allied Corp. announced that following an extensive regulatory review, it has received ANVISA approval for Brazilian importation. On April 27th, 2022 Allied announced the signing of a forward purchase agreement for the manufacturing and sell-through of medical products destined for Brazil. On June 09, 2022 Allied further announced the successful initial shipment for this forward purchase agreement. By way of this announcement, Allied has now obtained ANVISA approval for these transactions. The Brazilian Health Regulatory Agency (ANVISA) controls the importation of medical products to the Brazilian market. ANVISA’s role is to promote the protection of the population’s health by executing sanitary control of the production, marketing and use of products and services subject to health regulation, including related environments, processes, ingredients and technologies, as well as the control of ports, airports and borders. Allied has now met the required regulatory requirements for Brazilian ANVISA and is now importing into the Brazilian medical market. Tillkännagivande • Jul 15
Allied Corp. announced delayed 10-Q filing On 07/14/2022, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Apr 15
Allied Corp. announced delayed 10-Q filing On 04/14/2022, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Apr 06
Allied Corp Commends Colombian Government for Announcing the Final Approval of the Regulations for the Export of Cannabis from Colombia Allied Corp. commended the Colombian Government for the final approval of Regulation 227 (the "Regulation") which describes the technical guidelines regarding the export of cannabis flower from Colombia. On July 23, 2021, the President of Colombia, President Ivan Duque, signed Decree 811 lifting the prohibition on exportation of dried cannabis flower from Colombia. In October 2021, Allied was asked to provide first comment on the Regulation and then in November 2021, second comment. On February 20, 2022, Regulation 227 was officially announced by the President of Colombia introducing the practical regulations and implementation plan for the export of cannabis flower. On April 01, 2022, the Colombian Government has released final approval of the technical guidelines necessary for the export of cannabis flower. This, among other important advances, will enable Allied to begin exporting dried cannabis flower internationally to countries where it is legal to do so. Of note, the United States still has a legal limit of 0.3% THC. While only a few Colombian companies have been able to successfully export cannabis derivatives such as CBD distillate and isolate, up until now, the export of dried flower from Colombia has been prohibited. Allied has successfully shipped to several international markets and will now be submitting for multiple export requests for dried cannabis flower destined for international markets. Tillkännagivande • Jan 16
Allied Corp. announced delayed 10-Q filing On 01/14/2022, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Nov 30
Allied Corp. announced delayed annual 10-K filing On 11/29/2021, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Sep 21
Allied Corp. Announces Approval of Second CBD Isolate Import Permit for Australia and Submits Application for the Import of Dried Cannabis Allied Corp. announced that it has received approval of a second import permit for export of CBD isolate produced at Allied’s Colombian campus that is destined for the Australian market. In addition to this, through its Australian partner, Allied has submitted its first import permit to the Australian Department of Health for the import of dried cannabis flower. This dried flower import permit application is the first of its kind for Allied. This import application was made following the announcement made by the President of Colombia announcing the expansion of Colombia’s ability to export dried cannabis flower. Allied’s Australian partner has been in the pharmaceutical, medical device and medical supply for 30 years including being a Prime Vendor to the ADF (Australian Defense Forces) for 10 of those years. This has included supplying small medical devices, consumable and pharmaceutical needs (on and off continent). Over the past 4 years, Allied’s Australian partner has become expert in, and has supported the Australian government in, growing innovative new markets including: unregistered specialty medicines, devices for reduction of nicotine addiction, Psilocybin products, medicinal cannabis with secure storage and nationwide distribution as well as export and import. Tillkännagivande • Aug 26
Allied Corp. Initiates Additional Shipment of 200kgs of CBD Distillate From Colombia to Nevada, United States Allied Corp. announced that it has received approval from the Colombian Ministry of Justice to initiate a shipment of 200kgs of extracted CBD distillate product (containing less than 0.3% THC) to the United States. This shipment is specifically destined for the State of Nevada, which includes Las Vegas and Reno, and represents Allied’s shipment of CBD distillate product (containing less than 0.3% THC) to date. Allied is focusing on the State of Nevada, among other States, because believe a demonstration of the ability to produce CBD (containing less than 0.3% THC) in Colombia and its shipment to the United States, will allow them to be better positioned for US national legalization if and when it occurs. Given that the city of Las Vegas gets approximately 42 million visitors yearly (according to the Las Vegas Convention and Visitors Authority), there will be a large population of consumers coming from all over the world that will have exposure to CBD (containing less than 0.3% THC) products. Tillkännagivande • Jun 15
Allied Corp. announced a financing transaction Allied Corp. (OTCPK:ALID) announced that it will receive $525,000 in funding on June 14, 2021. The company will issue common stock in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. The minimum investment accepted from any outside investor is $10,000. Tillkännagivande • Apr 16
Allied Corp. announced delayed 10-Q filing On 04/15/2021, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Mar 19
Allied Corp. Files Provisional Patent for Psilocybin Therapeutic Invention Seeking Drug Indication for Mental Health Depression and Anxiety Applications Allied Corp. announced that it has submitted a provisional patent for the Allied therapeutic formulation and treatment regimen involving a prescription drug followed by a prophylactic daily drug formulation. These two products together administered under a novel treatment regimen is intended to be tested through the Allied clinical trial infrastructure to seek a drug indication for general depression and anxiety. This provisional patent contemplates the full scope treatment of general depression and anxiety with a proprietary Rx prescription medication followed by a daily prophylactic dose of proprietary medicinal compositions. This includes a proprietary dosing and therapeutic regimen of psilocybin, additional functional mushrooms and cannabinoid therapeutics. Among the various aspects of the present invention contemplated in the provisional patent sub- mission are compositions, formulations, methods for modulating endocannabinoid system activity, for modulating neuro-steroid biosynthesis, and for modulating neurotransmission, and methods for treating mental health disorders and improving mental health, using synergistic combinations of psilocybin, cannabinoids, and other active agents, provided in distinct daily dosing regimens. The content contemplated in the provisional patent submission describes the real world pharmaceutical formulations that Allied intends to research via human clinical trials in order to seek a drug indication. Tillkännagivande • Mar 10
Allied Corp. Receives ICA Approval for Psychoactive THC Strains Allied Corp. announced that its subsidiary Allied Colombia SAS has received approval from the Colombian Institute of Agriculture for the cultivation of its proprietary psychoactive cannabis strains. All 10 strains were approved and have passed all of the ICA requirements to be able to cultivate the high THC plants. Allied will now apply for a psychoactive export quota under the Colombian regime. The psychoactive seed evaluation approval was over a year-long process that began with the registration of the ten (10) novel psycho active (THC based) Allied strains with the national cultivar registry. Each strain was then germinated into plantlets in Allied’s scientific cultivation center in Colombia. Following germination, the plants entered into field trials that included rigorous data collection, analysis and phenotyping of the strains while in the vegetation life cycle. During this time, the strains were provided with propriety nutrients, handled with standard operating procedures and guided towards the plant flowering phase. Proprietary nutrients and procedures were also adhered to during the flowering phase and detailed batch record audit data were diligently collected during every day of the plant life cycle. Following flowering, the plants were harvested and tested for cannabinoid profiles and quality assurance testing parameters. The harvested material was then sent to an accredited laboratory for testing was and tested by high performance liquid chromatography (HPLC) testing methods. The lab results showed a higher cannabinoid profile from being grown in the Colombian climate when compared to the same strains grown in North American climate. The lab results, batch records and procedural archives were also submitted to the Colombian Institute of Agriculture and a day-long presentation was provided by Allied’s team. Tillkännagivande • Jan 15
Allied Corp. announced delayed 10-Q filing On 01/14/2021, Allied Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC. Tillkännagivande • Dec 26
Allied Corp. (OTCPK:ALID) entered into a letter of intent to acquire Pacific Sun Fungi. Allied Corp. (OTCPK:ALID) entered into a letter of intent to acquire Pacific Sun Fungi on December 20, 2020. Tillkännagivande • Dec 13
Allied Corp. Goes Live with US Sales of Equilibrium Bio CBD Electrolyte Replacement Rehydration Drinks Allied Corp. announced the completion of the first manufacturing run of Hydro Sport CBD-infused rehydration drinks from Allied’s latest brand Equilibrium Bio. As well, these drinks have also been produced for the Tactical Relief™ branding as Tactical Hydration electrolyte replacement and rehydration drink products. The first Equilibrium Bio products known as Hydro Sport are available for purchase on e-commerce platforms and have also been shipped to national retail buyers throughout the US. The first manufactured batch encompasses six unique product SKUs (stock-keeping units). The CBD-infused drink pouches come in three flavors: Lemon Lime, Berry Fresh and Orange Burst. The all-natural flavoring and ingredients in the drinks include: Filtered Water, CBD 20 (mg), CBD, CBG, Sodium Citrate, Citric Acid, Sea Salt, Natural Flavor, Tripotassium Citrate, Vitamin B Complex, Ascorbic Acid (Vitamin C), Sucralose, Acesulfame Potassium and Beta Carotene for color. The Hydro Sport drinks are the first electrolyte replacement drink to offer CBD, CBG and CBN and have been designed to aide athletes to relax and recover. Equilibrium Bio™ is a lifestyle brand that is focused on everything athletic. From High Intensity Interval Training workouts to Ironman races to general athletic consumers, Equilibrium Bio products are there with the athlete along the entire competitive journey. Rehydration and electrolyte replacement is a primary focus for this brand and its products. Tillkännagivande • Dec 01
Allied Corp. announced delayed annual 10-K filing On 11/30/2020, Allied Corp. announced that they will be unable to file their next 10-K by the deadline required by the SEC. Tillkännagivande • Oct 17
Allied Signs Monthly Recurring Purchase Order for Sale of Proprietary Cannabis Product Allied Corp. has now signed its first monthly recurring purchase order. Allied is an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues. Allied announced the signing of its first monthly recurring forward purchase agreement with Mistral Consulting Group for the sale of Allied’s proprietary cannabis products. The agreement consists of a monthly recurring purchase order of extracted cannabis products in quantities scaling from 1-5kgs per month to 50kgs per month for each month between November 2020 and March 2021. Both parties have written into the agreement that they anticipate this monthly quantity to scale to larger quantities beyond the 50kgs per month. The term of the agreement is set for a 12 month recurring monthly purchase cycle with the option to continue for another 5 years beyond the first 12 months. The product under the purchase order will meet quality assurance standards such as the testing parameters contained in the European Pharmacopeia standards for the US and European markets, GACP (Good Agricultural Collection Practice) Standards, and GPP (Good Production Practices) to meet the standards for the Canadian market. The achievement of these criteria will be evidenced by the detailed batch records and certificates of analysis laboratory testing results that Allied performs for each harvested batch. Tillkännagivande • Oct 08
Allied Corp. Signs Definitive Agreement for the Launch of CBD-Infused Electrolyte Replacement Drink for Veterans and Athletes Allied Corp. announced the signing of a definitive agreement to launch a new CBD-infused electrolyte replacement drink with the Cannabis company Reef Drink Company. The first product to be produced under the Agreement will be a CBD-infused electrolyte and rehydration drink targeted at veteran and first responders as an extension of the Tactical Relief™ brand. This product will be called Tactical Hydration and launched under the Tactical Relief™ brand. In addition to this, a second Allied Corp. brand has now been launched called Equilibrium Bio. As with the Tactical Relief™ brand, the Equilibrium Bio brand is owned, managed and supported by Allied Corp. This brand will represent health and wellness products targeted at both male and female athletic consumers. The first product will be called “Hydration Blast” by Equilibrium Bio. All produced and supported by Allied. Tactical Hydration and Hydration Blast products will provide a CBD-infused drink for rehydration with sodium citrate electrolyte replacement supplements for athletic and veteran consumers. Both the Tactical Relief and Equilibrium Bio drinks will be available in fruit punch, lemon lime and orange flavors. Allied has additional products in the Equilibrium Bio and Tactical Relief product pipeline. Allied anticipates the first 15,000 sample drink products being ready for wholesale purchasers within October 2020. From these 15,000 sample products, it will be pursuing purchase orders and national distribution. Tillkännagivande • Jul 30
Allied Corp. (OTCPK:ALID) completed the acquisition of Medicolombia’s Cannabis S.A.S. from Dorson Commercial Corp. for $7.6 million. Allied Corp. (OTCPK:ALID) entered into a share purchase agreement to acquire Medicolombia’s Cannabis S.A.S. from Dorson Commercial Corp. for $7.3 million on August 29, 2019. Pursuant to the agreement, Allied will acquire all of the issued and outstanding shares of Medicolombia’s Cannabis in exchange for $0.7 million and 4.5 million shares of Allied. At August 31, 2019, Allied had paid a $0.7 million deposit and advanced funds for operations. At August 31, 2019, $1.16 million had been advanced to Dorson Commercial Corp. and was recorded as a prepaid and deposit. At November 30, 2019, the $1.01 million had been advanced to Dorson Commercial Corp. and was recorded as an advance.
Allied Corp. (OTCPK:ALID) completed the acquisition of Medicolombia’s Cannabis S.A.S. from Dorson Commercial Corp. for $7.6 million on February 17, 2020. During the period leading up to the acquisition, Allied Corp. made additional advances to Dorson Commercial Corp. and Medicolombia’s Cannabis S.A.S. totaling $0.3 million. 